KCL in D5W
"July 23, 2015 -- The smallest ingredients found in certain food products are raising concerns among some scientists and food safety advocates.
Known as nanoparticles, these tiny additives -- most often used to make foods more visually appea"...
KCL in D5W
DOSAGE AND ADMINISTRATION
These solutions are for intravenous use only.
Dosage is to be directed by a physician and is dependent upon age, weight, clinical condition of the patient and laboratory determinations. Frequent laboratory determinations and clinical evaluation are essential to monitor changes in blood glucose and electrolyte concentrations, and fluid and electrolyte balance during prolonged parenteral therapy.
Fluid administration should be based on calculated maintenance or replacement fluid requirements for each patient.
If the serum potassium level is greater than 2.5 mEq/liter, potassium chloride should be given at a rate not to exceed 10 mEq/hour in a concentration less than 30 mEq/liter. The total 24-hour dose should not exceed 200 mEq.
If urgent treatment is indicated (serum potassium level less than 2.0 mEq/liter with electrocardiographic changes or paralysis), potassium chloride may be infused at a rate of 40 mEq/hour. As much as 400 mEq may be administered in a 24-hour period while monitoring blood electrolyte concentrations carefully.
Dextrose may be administered to normal individuals at a rate of 0.5 g/kg/hour without producing glycosuria. At the maximum infusion rate of 0.8 g/kg/hour, approximately 95% of the dextrose is retained. Pediatric Dosage and Administration. There is no specific pediatric dose. The dose is dependent on weight, clinical condition and laboratory results. See WARNINGS and PRECAUTIONS.
Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques. Mix thoroughly. Do not store.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Potassium Chloride in 5% Dextrose Injections USP (potassium chloride in 5% dextrose injection) are supplied sterile and nonpyrogenic in 1000 mL EXCEL® Containers packaged 12 per case.
|0.15% Potassium Chloride in 5% Dextrose Injection USP (20 mEq K+/liter) (Canada DIN 01931539)|
|0.30% Potassium Chloride in 5% Dextrose Injection USP (40 mEq K+/liter) (Canada DIN 01967770)|
Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended that the product be stored at room temperature (25°C); however, brief exposure up to 40°C does not adversely affect the product.
Directions for Use of EXCEL® Container
Caution: Do not use plastic container in series connection.
Tear overwrap down at notch and remove solution container. Check for minute leaks by squeezing solution container firmly. If leaks are found, discard solution as sterility may be impaired. If supplemental medication is desired, follow directions below before preparing for administration.
NOTE: Before use, perform the following checks:
Inspect each container. Read the label. Ensure solution is the one ordered and is within the expiration date.
Invert container and carefully inspect the solution in good light for cloudiness, haze, or particulate matter. Any container which is suspect should not be used.
Use only if solution is clear and container and seals are intact.
Preparation for Administration
- Remove plastic protector from sterile set port at bottom of container.
- Attach administration set. Refer to complete directions accompanying set.
To Add Medication
Warning: Some additives may be incompatible.
To Add Medication Before Solution Administration
- Prepare medication site.
- Using syringe with 18-22 gauge needle, puncture medication port and inner diaphragm and inject.
- Squeeze and tap ports while ports are upright and mix solution and medication thoroughly.
To Add Medication During Solution Administration
- Close clamp on the set.
- Prepare medication site.
- Using syringe with 18-22 gauge needle of appropriate length (at least 5/8 inch), puncture resealable medication port and inner diaphragm and inject.
- Remove container from IV pole and/or turn to an upright position.
- Evacuate both ports by tapping and squeezing them while container is in the upright position.
- Mix solution and medication thoroughly.
- Return container to in use position and continue administration.
Revised: January 2004. B. BRAUN Medical Inc., Irvine, CA USA 92614-5895. In Canada, distributed by: B. Braun Medical Inc. Scarborough, Ontario M1H 2W4. FDA rev date: 9/27/2004This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 12/3/2008
Additional KCL in D5W Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Weight Loss Wisdom
Get tips, recipes and inspiration.